Institute of Public Health and Management, Clarke International University, P.O. Box 7782, Kampala, Uganda.
Department of Community Health, Faculty of Medicine, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara, Uganda.
BMC Infect Dis. 2021 Jun 1;21(1):511. doi: 10.1186/s12879-021-06244-y.
Discontinuation of tuberculosis treatment (DTT) among children in sub-Saharan Africa is a major obstacle to effective tuberculosis (TB) control and has the potential to worsen the emergence of multi-drug resistant TB and death. DTT in children is understudied in Uganda. We examined the level and factors associated with DTT among children at four large health facilities in Kampala Capital City Authority and documented the reasons for DTT from treatment supporters and healthcare provider perspectives.
We conducted a retrospective analysis of records for children < 15 years diagnosed and treated for TB between January 2018 and December 2019. We held focus group discussions with treatment supporters and key informant interviews with healthcare providers. We defined DTT as the stoppage of TB treatment for 30 or more consecutive days. We used a stepwise generalized linear model to assess factors independently associated with DTT and content analysis for the qualitative data reported using sub-themes.
Of 312 participants enrolled, 35 (11.2%) had discontinued TB treatment. The reasons for DTT included lack of privacy at healthcare facilities for children with TB and their treatment supporters, the disappearance of TB symptoms following treatment initiation, poor implementation of the community-based directly observed therapy short-course (CB-DOTS) strategy, insufficient funding to the TB program, and frequent stock-outs of TB drugs. DTT was more likely during the continuation phase of TB treatment compared to the intensive phase (Adjusted odds ratio (aOR), 5.22; 95% Confidence Interval (CI), 1.76-17.52) and when the treatment supporter was employed compared to when the treatment supporter was unemployed (aOR, 3.60; 95% CI, 1.34-11.38).
Many children with TB discontinue TB treatment and this might exacerbate TB morbidity and mortality. To mitigate DTT, healthcare providers should ensure children with TB and their treatment supporters are accorded privacy during service provision and provide more information about TB symptom resolution and treatment duration versus the need to complete treatment. The district and national TB control programs should address gaps in funding to TB care, the supply of TB drugs, and the implementation of the CB-DOTS strategy.
在撒哈拉以南非洲地区,儿童结核病治疗中断是有效控制结核病的主要障碍,有可能加剧耐多药结核病的出现和死亡。在乌干达,儿童结核病治疗中断问题研究较少。我们在坎帕拉首都行政区的四家大型卫生机构中,研究了儿童结核病治疗中断的程度和相关因素,并从治疗支持者和医疗保健提供者的角度记录了治疗中断的原因。
我们对 2018 年 1 月至 2019 年 12 月期间诊断和治疗的<15 岁儿童的记录进行了回顾性分析。我们与治疗支持者进行了焦点小组讨论,并对医疗保健提供者进行了关键知情人访谈。我们将结核病治疗中断定义为停止结核病治疗 30 天或以上。我们使用逐步广义线性模型评估与结核病治疗中断相关的独立因素,并使用子主题对报告的定性数据进行内容分析。
在纳入的 312 名参与者中,有 35 名(11.2%)停止了结核病治疗。结核病治疗中断的原因包括为结核病儿童及其治疗支持者提供的医疗保健设施缺乏隐私、治疗开始后结核病症状消失、社区直接观察治疗短期疗程(CB-DOTS)策略执行不力、结核病规划资金不足以及结核病药物经常缺货。与强化期相比,结核病治疗的继续期更有可能出现结核病治疗中断(调整后的优势比(aOR),5.22;95%置信区间(CI),1.76-17.52),与治疗支持者失业相比,治疗支持者就业时更有可能出现结核病治疗中断(aOR,3.60;95%CI,1.34-11.38)。
许多结核病儿童停止了结核病治疗,这可能会加剧结核病的发病率和死亡率。为了减少结核病治疗中断,医疗保健提供者应确保结核病儿童及其治疗支持者在提供服务时享有隐私,并提供更多关于结核病症状缓解和治疗持续时间与完成治疗的必要性的信息。地区和国家结核病控制规划应解决结核病护理资金、结核病药物供应和 CB-DOTS 策略实施方面的差距。